ELOX Company Profile and Key Details

ELOX has shown weak momentum, losing -18.57% over the past week and -48.13% over the past quarter, though year-to-date performance is down -27.39%. Average 10-day trading volume of 78.17 thousand shares is significantly above the 3-month average of 15.87 thousand, indicating heightened recent market interest.

Eloxx Pharmaceuticals, Inc. generated EPS of -$11.22 over the past year. Five-year average earnings growth is 38.55%. The latest quarter delivered EPS of -$0.08. The next quarter is forecast at -$1.97. Next year's EPS is expected at $6.57. Eloxx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by -98.78%. The prior quarter beat by -33.5%. Over the last six quarters, Apple has recorded several small beats. These include 88.55% in March 30, 2023.

Eloxx Pharmaceuticals, Inc. has 3.14 million shares outstanding. The public float is 2.91 million shares, elevated short interest at 0.80% of float. This equals 21.48 thousand shares. The short ratio is 0.66 days. Institutional investors hold 4.22% of the float. Insiders own 5.82%. FORBES CHRISTOPHER holds 12.76 million shares, Shabtai Gilad has 3.35 million shares and Kleijwegt Martijn has 2.95 million shares.

Eloxx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.38. This means the shares are trading above this model’s fair value.

Eloxx Pharmaceuticals, Inc. (OTC:ELOX) closed at $13.98 USD, gaining $0.05 (0.36%) from the previous close of $13.93. The stock is currently mid-range between its 52-week high and low $8.20 and $17.50. With a market capitalization of about $105.87 million, Eloxx Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-24.60). Key stats such as the average daily volume over the past year has been around 78.91 thousand shares, volume is running light vs its 52-week average. Headquartered in Watertown, MA, Eloxx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sumit Aggarwal, the company employs approximately 18 people and listed since April 26, 1999. Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation.

Eloxx Pharmaceuticals, Inc. trades at a P/E ratio of -10.58, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -7.62 indicating negative book value, which may reflect financial stress. The P/FCF stands at -23.51, also above market averages.

Our AI price prediction model suggests that Eloxx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 19.96%, with price expected at $16.77 by July 02, 2026, within a range of $13.81 to $19.49 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by September 16, 2026, with a range of $0.00 to $1.01. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by June 18, 2027, within a range of $0.00 to $2.56.

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) shares are down -27.39% year-to-date Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Eloxx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -10.58. Our AI forecast model points to short-term strength (19.96% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.